NCT03729180
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 7 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Aug 22, 2027 to Aug 22, 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 5 words
- Secondary endpoints: details revised at 1 of 6 entries
- Site contact updated
- Publications: details revised at 3 of 3 entries
- Minor Collaborators expanded, about 6 wordsv10
- Notable Primary and study completion dates: Aug 22, 2025 to Aug 22, 2027v9
- Notable Primary completion date: Aug 22, 2023 to Aug 22, 2025v7
- Minor Study title expanded, about 3 wordsv3
Notable Phase: Not specified to Not applicablev2 Show 8 more changesShow less
- Trial status: Not Yet Recruiting to Recruiting
- Enrollment target: 1000 to 1900
- Primary completion date: Oct 7, 2022 to Aug 22, 2023
- Study sites: 0 to 1
- Study completion date: Oct 7, 2024 to Aug 22, 2025
- Start date changed from estimate of Oct 7, 2019 to Jan 22, 2019
- Interventions: Blood test for genetic testing (Diagnostic Test), Drug-genetic Profile (Other), Routine Elective Surgery (Procedure) to Blood test for genetic testing (Diagnostic Test), Drug-genetic Profile (Other), Routine Elective Surgery- In patient or out patient…
- Secondary endpoints: details revised at 6 of 6 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.
All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.
All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
Procedures: Routine Elective Surgery- In patient or out patient elective surgery
Diagnostic tests: Blood test for genetic testing
Other: Drug-genetic Profile
Sites
1 site in 1 country
- University Of Chicago Medicine Comprehensive Cancer CenterChicago, Illinois, United States